drugset / Trial / NCT01546623

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

NCT01546623

Phase 3 Completed 160 enrolled Takeda
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) against TAP-144-SR(3M) in prostate cancer patients previously treated with hormonal therapy.

Timeline

Start
2012-03
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Leuprolide Other / unclassified 11.25 mg
Subject Leuprolide Other / unclassified 22.5 mg

Indications